3,000
Participants
Start Date
March 1, 2025
Primary Completion Date
February 29, 2028
Study Completion Date
February 28, 2030
Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE.
Quasar is a biologically-informed multi-agent system developed based on multi-omics and multi-modal data. By integrating multidimensional information such as patients' demographic, clinical, and omics data (including DNA genotyping, whole-exome sequencing, transcriptome sequencing, etc.), it prioritizes standard treatment plans and recommends the optimal personalized treatment plan. Including targeted drugs, chemotherapy, immunotherapy approved by China CDE.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Langfang Branch), Langfang
NING LI
OTHER